Industry analysis
Healthcare Research, Analytics & Technology
Read from what its listed companies are showing. Valuations are compared within this industry.
Mixed
11 listed companies · ₹ 39,370 Cr. total market value- ▲70% of companies grew sales by more than 8% from a year earlier; the typical company's profit rose 0%. 18% made a loss.
- ●No credit rating changes in the last 90 days.
- –No good and 2 bad company announcements (read since 6 Oct 2026; not counted until there is a month of them).
- ▼The typical share is down 11% in 3 months; 38% of shares trade above their 200-day average (their usual level).
- –Typical P/E 34.7, 13% above these companies' usual level (pricier than normal).
▲ / ▼ / ● are the signals the verdict counts: results, credit ratings, announcements and share prices. Lines marked – are shown but not counted.
In charts
Share prices over the last year
The typical Healthcare Research, Analytics & Technology share against the typical share on the market, both starting at 100. Now 97 vs 83.
Is growth speeding up or slowing down?
The typical company's sales and profit growth against the same quarter a year earlier.
Cheaper than peers
Not a buy list. These shares trade at a P/E at least 30% below their industry's typical level and below their own usual level, and they also pass basic checks: profitable, sales and profit growing, low debt, no red flags, market value of ₹250 Cr or more. Cheap shares are often cheap for a reason; this is where to start reading, not where to stop.
No company here passes every test right now.
Cheaper than peers across the whole market
Leaders and laggards
Good news
No green flags in 90 days.
Warning signs
- Syngene InternationalSenior exit
Best shares, 3 months
- Bilcare+39.9%
- Indegene+14.2%
- Jeevan Scientific Technology+13.6%
- Syngene International−2.2%
- Adeshwar Meditex−6.7%
Worst shares, 3 months
- Take Solutions−48.8%
- Vanta Bioscience−19.3%
- Fabtech Technologies−15.8%
- Suven Life Sciences−15.1%
- Vimta Labs−14.9%
Companies
Click a column to sort.
Figures are medians and shares of companies, so one giant company cannot outweigh the rest. Results compare each company's latest quarter with the same quarter a year earlier; ratings and announcements cover the last 90 days (announcements are read by AI and can be wrong). This page adds up published data; it is not a recommendation to buy or sell anything.